VIR Vir Biotechnology

Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024

SAN FRANCISCO--(BUSINESS WIRE)--

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

EN
30/04/2024

Underlying

VIRVir Biotechnology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vir Biotechnology

 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Pr...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data on June 5. The update will include data on participants that have reached 12 and 24 weeks of ch...

10h / 15m 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Provides Corporate Update and Reports First Quarter ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “Our team has worked diligently to streamline our operations and reduce costs,...

May 2, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Participate in the BofA Securities Healthcare Con...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is an immunology company focused on powering the immune syst...

April 30, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D....

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”). If elected, each of Drs. Bischofberger and Farid will join the Board on such date. The nomination of the two new independent directors demonstrates Vir’s commitment to ongoing Board refreshment. Drs. Bischofberger and Farid bring extensive mid-to-late-stage clinical development and computat...

April 18, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Provide Business Update and Report First Quarter ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at . Participants may access the conference call via webcast on the Events & Present...

April 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch